Typhim Vi recall
October 9, 2012
SANOFI- Aventis is recalling some
batches of its Typhim Vi Vaccine
(Salmonella typhi Vi
polysaccharide typhoid vaccine)
because they may have lower than
expected antigen content, which
may result in reduced efficacy.
The issue resulted from a
problem with the filling process at
one of Sanofi’s manufacturing
facilities.
The affected batch cartons
include: E1246-3, G0461-2,
H0078-3, H0078-4, H0101-1,
H0198-5 and H0507-1.
Other batches of Typhim Vi
Vaccine are not affected and can
still be used.
For consumers who have had the
vaccination from the recalled
batches, Sanofi Pasteur has said
that whilst they may have received
less than the intended amount of
antigen, the manufacturer is not
recommending revaccination
earlier than otherwise.
Meanwhile the TGA advises
individuals who are planning to
travel to regions where typhoid is
endemic to discuss their individual
situation with a health professional
or travel doctor.
At present Sanofi Pasteur is
looking to source unaffected
batches of the vaccine as quickly
as possible, however it has warned
that there may be a shortage until
normal supply resumes in early 2013.
In the vaccine’s absence the TGA
has named three alternative
products that may be used:
Typherix (GSK), Vivotif (CSL), and ·
Vivaxim (Sanofi) - a product which
also contains hepatitis A.
See www.tga.gov.au for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Oct 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Oct 12
